Global Dopamine Receptor Agonists For PD Market Growth (Status and Outlook) 2025-2031

The global Dopamine Receptor Agonists For PD market size is predicted to grow from US$ 798 million in 2025 to US$ 1012 million in 2031; it is expected to grow at a CAGR of 4.0% from 2025 to 2031.

Dopamine receptor agonists are a class of drugs that mimic the action of dopamine by stimulating dopamine receptors in the brain. These medications are primarily used to treat neurological disorders such as Parkinson’s disease by compensating for the loss of dopamine-producing neurons. By activating dopamine receptors, they help improve motor control, reduce tremors, and alleviate symptoms associated with dopamine deficiency.

United States market for Dopamine Receptor Agonists For PD is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Dopamine Receptor Agonists For PD is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Dopamine Receptor Agonists For PD is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Dopamine Receptor Agonists For PD players cover Boehringer Ingelheim, Krka, Jingxin Pharma, Novartis, Qilu Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Dopamine Receptor Agonists For PD Industry Forecast” looks at past sales and reviews total world Dopamine Receptor Agonists For PD sales in 2024, providing a comprehensive analysis by region and market sector of projected Dopamine Receptor Agonists For PD sales for 2025 through 2031. With Dopamine Receptor Agonists For PD sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dopamine Receptor Agonists For PD industry.

This Insight Report provides a comprehensive analysis of the global Dopamine Receptor Agonists For PD landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Dopamine Receptor Agonists For PD portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dopamine Receptor Agonists For PD market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dopamine Receptor Agonists For PD and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dopamine Receptor Agonists For PD.

This report presents a comprehensive overview, market shares, and growth opportunities of Dopamine Receptor Agonists For PD market by product type, application, key players and key regions and countries.

Segmentation by Type:
Pramipexole
Piribedil
Ropinirole
Other

Segmentation by Application:
Hospital
Retail Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim
Krka
Jingxin Pharma
Novartis
Qilu Pharma
Euro-Pharma
Torrent Pharmaceuticals
Teva
CSPC
Sun Pharmaceutical
Les Laboratoires Servier
Desitin Arzneimittel
GlaxoSmithKline
Ruien Pharma
Kyowa Kirin
Huahai Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.